デフォルト表紙
市場調査レポート
商品コード
1522138

切れ痔(裂肛)治療市場:世界の産業規模、シェア、動向、機会、予測、治療タイプ別、投与経路別、流通チャネル別、地域別、競合別、2019年~2029年

Anal Fissure Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By Route of Administration, By Distribution Channel, By Region and Competition, 2019-2029F


出版日
ページ情報
英文 185 Pages
納期
2~3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

切れ痔(裂肛)治療市場:世界の産業規模、シェア、動向、機会、予測、治療タイプ別、投与経路別、流通チャネル別、地域別、競合別、2019年~2029年
出版日: 2024年07月26日
発行: TechSci Research
ページ情報: 英文 185 Pages
納期: 2~3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

切れ痔(裂肛)治療の世界市場は、2023年に13億8,000万米ドルと評価され、2029年までのCAGRは6.23%で、予測期間中に着実な成長を予測しています。

裂肛は、肛門の内壁に小さな裂け目や切れ目ができ、排便時に痛みや不快感、時には出血を引き起こします。裂肛の治療オプションは、症状の重症度や持続性によって異なります。切れ痔(裂肛)治療の市場では、症状の緩和、治癒の促進、再発予防を目的としたさまざまな選択肢が提供されています。ぬるめのお湯に10~15分浸かる(座浴)ことを毎日数回行うことで、肛門の筋肉をリラックスさせ、治癒を助けることができます。

市場概要
予測期間 2025-2029
市場規模:2023年 13億8,000万米ドル
市場規模:2029年 19億6,000万米ドル
CAGR:2024年-2029年 6.23%
急成長セグメント カルシウム拮抗薬
最大市場 北米

手術以外の方法としては、ニトログリセリンやカルシウム拮抗薬のような外用薬を使用し、内肛門括約筋を弛緩させて治癒を促進する方法や、炎症を抑えるステロイド外用薬を使用する方法があります。便を軟らかくし、排便時の負担を軽減するために、便軟化剤やサイリウムハスクなどの食物繊維サプリメントが一般的に使用されます。側方内括約筋切開術、ボツリヌス毒素注射、レーザー括約筋切開術などの外科的および低侵襲的処置は、痙攣を緩和し治癒を促進するために、その下にある括約筋を標的とします。血小板豊富血漿注射や幹細胞治療のような新しい治療法は、組織の修復を促進する可能性を示しています。

ボツリヌス毒素注射やレーザー治療などの低侵襲手技の技術的進歩は、回復時間や術後の不快感を軽減することから人気を集めています。外用薬は、外科的選択肢と比較して費用対効果が高く、利用しやすいため、依然として好ましい初期治療法です。現在進行中の調査では、治療成績の改善、再発率の低下、再生医療のような革新的な治療アプローチの探求に重点が置かれています。

主な市場促進要因

高齢者人口の増加と不健康なライフスタイル

技術の進歩と治療オプション

主な市場課題

治療コスト

限られた認識と診断

主要市場動向

再生医療における新たな治療法

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界の切れ痔(裂肛)治療市場に与える影響

第5章 世界の切れ痔(裂肛)治療市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 治療タイプ別(下剤、局所硝酸塩、カルシウム拮抗薬、便軟化剤、手術、その他)
    • 投与経路別(経口、外用、その他)
    • 流通チャネル別(病院薬局、小売薬局、オンライン薬局)
    • 地域別
    • 企業別(2023)
  • 市場マップ

第6章 アジア太平洋地域の切れ痔(裂肛)治療市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 治療タイプ別
    • 投与経路別
    • 流通チャネル別
    • 国別
  • アジア太平洋地域:国別分析
    • 中国
    • インド
    • オーストラリア
    • 日本
    • 韓国

第7章 欧州の切れ痔(裂肛)治療市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 治療タイプ別
    • 投与経路別
    • 流通チャネル別
    • 国別
  • 欧州:国別分析
    • フランス
    • ドイツ
    • スペイン
    • イタリア
    • 英国

第8章 北米の切れ痔(裂肛)治療市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 治療タイプ別
    • 投与経路別
    • 流通チャネル別
    • 国別
  • 北米:国別分析
    • 米国
    • メキシコ
    • カナダ

第9章 南米の切れ痔(裂肛)治療市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 治療タイプ別
    • 投与経路別
    • 流通チャネル別
    • 国別
  • 南米:国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの切れ痔(裂肛)治療市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 治療タイプ別
    • 投与経路別
    • 流通チャネル別
    • 国別
  • 中東・アフリカ:国別分析
    • 南アフリカ
    • サウジアラビア
    • UAE
      • 市場規模・予測
        • 金額別
      • 市場シェア・予測
        • 治療タイプ別
        • 投与経路別
        • 流通チャネル別

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の動向
  • 製品上市
  • 合併と買収

第13章 世界の切れ痔(裂肛)治療市場:SWOT分析

第14章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第15章 競合情勢

  • AbbVie Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • RDD Pharma Ltd.
  • Cipla Limited
  • Sanofi SA
  • Boehringer Ingelheim International GmbH
  • Troikaa Pharmaceuticals Ltd.
  • Kyowa Kirin Co., Ltd.
  • Lupin Limited

第16章 戦略的提言

第17章 調査会社について・免責事項

目次
Product Code: 24367

Global Anal Fissure Treatment Market was valued at USD 1.38 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 6.23% through 2029. An anal fissure refers to a small tear or cut in the lining of the anus, causing pain, discomfort, and sometimes bleeding during bowel movements. The treatment options for anal fissures vary depending on the severity and persistence of symptoms. The market for anal fissure treatments offers a diverse range of choices designed to alleviate symptoms, promote healing, and prevent recurrence. Soaking in warm water (sitz baths) for 10 to 15 minutes several times daily can help relax the anal muscles and aid in healing.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 1.38 Billion
Market Size 2029USD 1.96 Billion
CAGR 2024-20296.23%
Fastest Growing SegmentCalcium Channel Blockers
Largest MarketNorth America

Non-surgical methods include using topical medications like nitroglycerin and calcium channel blockers, which relax the internal anal sphincter muscle to facilitate healing, as well as topical steroids to reduce inflammation. Stool softeners and fiber supplements such as psyllium husk are commonly utilized to soften stools and reduce strain during bowel movements. Surgical and minimally invasive procedures like lateral internal sphincterotomy, botulinum toxin injections, and laser sphincterotomy target the underlying sphincter muscle to relieve spasms and promote healing. Emerging therapies like platelet-rich plasma injections and stem cell therapy show potential in enhancing tissue repair.

Technological advancements in minimally invasive procedures such as botulinum toxin injections and laser therapy are gaining popularity due to reduced recovery times and post-operative discomfort. Topical medications remain a preferred initial treatment due to their cost-effectiveness and accessibility compared to surgical options. Ongoing research focuses on improving treatment outcomes, lowering recurrence rates, and exploring innovative therapeutic approaches like regenerative medicine.

Key Market Drivers

Growing Elderly Population and Unhealthy Lifestyles

As the global population ages, there is a notable increase in the occurrence of anal fissures. Elderly individuals are particularly vulnerable due to factors such as decreased tissue elasticity, chronic constipation, and other age-related health conditions. This demographic shift directly fuels the demand for anal fissure treatments, as older adults seek medical assistance to alleviate symptoms and improve their quality of life. According to the World Social Report 2023 published by the UN, the global population aged 65 years and older is expected to more than double, rising from 761 million in 2021 to 1.6 billion by 2050. In 2021, one in ten people worldwide were aged 65 or older, a proportion projected to increase to one in six by 2050. This demographic shift directly fuels the demand for anal fissure treatments, as older adults seek medical assistance to alleviate symptoms and improve their quality of life.

Lifestyle factors significantly impact individual health and quality of life, with approximately 60% of health-related outcomes associated with lifestyle choices, as reported by the World Health Organization (WHO). Conditions such as metabolic diseases, musculoskeletal issues, cardiovascular diseases, hypertension, obesity, and other health problems can result from these lifestyles. Modern sedentary habits, inadequate hydration, and poor dietary choices (including low fiber intake) contribute to constipation and increased straining during bowel movements. These factors are major contributors to the development of anal fissures across various age groups, not only the elderly. The market for anal fissure treatments benefits from the growing necessity to effectively manage and treat these conditions. The combination of an aging population and widespread unhealthy lifestyles has heightened awareness and diagnosis of anal fissures. More individuals are identifying symptoms early and seeking medical guidance, thereby expanding the market for treatment options.

Technological Advancements and Treatment Options

Advances in medical technology have spurred the development of minimally invasive treatments for anal fissures, such as botulinum toxin injections and laser therapy. These methods provide effective alternatives to traditional surgeries, offering shorter recovery times and reduced post-operative discomfort. Advanced imaging techniques and diagnostic tools enable healthcare providers to accurately diagnose anal fissures and tailor treatment plans, accordingly, thereby enhancing patient outcomes through timely and precise interventions.

In the field of regenerative medicine, promising therapies like platelet-rich plasma (PRP) injections and stem cell therapy show potential in promoting tissue repair and expediting healing processes for anal fissures. An article in Journal Nature published in 2023 discusses the evolving landscape of macrophage-based cell therapy, highlighting its clinical application in treating chronic anal fissures and other conditions. Clinical trials utilizing ex vivo polarization and adoptive transfer of macrophages are progressing, indicating the methodology's efficacy in regenerative medicine.

Technological advancements have also improved the formulation and delivery of topical medications used in anal fissure treatment, such as nitroglycerin ointment and calcium channel blockers. These medications aid in relaxing the anal sphincter muscle and facilitating healing. Research published in Diseases of the Colon & Rectum demonstrates that tocopherol acetate ointment has shown superior healing rates compared to glyceryl trinitrate ointment in managing chronic anal fissures. These technological advancements empower healthcare providers to deliver patient-centered care through personalized treatment plans and enhanced patient education. This approach empowers patients to actively participate in their treatment decisions and ongoing management. Overall, technological progress and the expansion of treatment options are pivotal in advancing the anal fissure treatment market by offering safer, more effective, and patient-friendly solutions. These developments cater to the growing demand for minimally invasive therapies and personalized care, ultimately enhancing treatment outcomes and patient satisfaction.

Key Market Challenges

Cost of Treatment

The cost of treating anal fissures poses a substantial challenge within the healthcare market, affecting patient access, treatment adherence, and the overall sustainability of healthcare systems. Costs can vary significantly based on the severity of the condition and the chosen treatment method. While conservative measures like dietary adjustments and over-the-counter medications are generally affordable, surgical procedures and newer therapies often come with substantial expenses. Patients frequently encounter considerable out-of-pocket costs for consultations, diagnostic tests, and medications such as nitroglycerin ointment or calcium channel blockers, as well as for surgical interventions. These expenses can strain household budgets, particularly for individuals lacking adequate insurance coverage.

High treatment costs can dissuade patients from seeking timely medical care or adhering to prescribed treatment plans. Financial constraints may lead individuals to opt for less effective or self-managed approaches, potentially prolonging symptoms and complicating recovery. Managing anal fissures, especially recurrent cases, demands significant healthcare resources, including physician time, diagnostic equipment, surgical facilities, and post-operative care. This contributes to escalated healthcare spending and challenges in resource allocation. Addressing these issues requires collaborative efforts to improve insurance coverage, promote cost-effective treatment strategies, foster innovation in healthcare delivery, and enhance patient education and support. By prioritizing these initiatives, stakeholders can work towards making effective anal fissure treatments more accessible and sustainable within healthcare systems.

Limited Awareness and Diagnosis

Anal fissures are often not promptly identified by patients or healthcare providers, leading to delays in diagnosis and treatment initiation. This delay can worsen symptoms and may necessitate more invasive treatments later. Due to the sensitive nature of the condition, which can cause embarrassment and discomfort, individuals can be reluctant to seek medical attention promptly. This stigma can contribute to delayed diagnosis and treatment initiation. Many people may not recognize the symptoms of anal fissures or may mistake them for hemorrhoids or other similar conditions. This lack of awareness can result in patients either not seeking appropriate medical care or attempting ineffective self-treatment methods.

Limited awareness and diagnosis represent significant obstacles for companies in the pharmaceutical and medical device sectors focused on treating anal fissures. They can face challenges in effectively reaching their target patient demographics and healthcare providers to promote their products. Educational campaigns aimed at both healthcare professionals and the public are crucial to improving awareness. These initiatives aim to enhance symptom recognition, encourage early diagnosis, and advocate for effective treatment options. Ultimately, such efforts are vital for benefiting patients and fostering growth in the market for anal fissure treatments.

Key Market Trends

Emerging Therapies in Regenerative Medicine

Regenerative medicine therapies are becoming increasingly prominent in the market for treating anal fissures. Stem cell therapy utilizes mesenchymal stem cells (MSCs) sourced from bone marrow or adipose tissue. MSCs possess regenerative properties capable of modulating inflammation, promoting tissue regeneration, and enhancing healing in anal fissures. This therapy shows promise in improving tissue repair and reducing fibrosis associated with chronic anal fissures. Clinical trials are currently investigating the safety and effectiveness of MSC-based treatments for this condition. Research published in the International Journal of Colorectal Disease demonstrated that autologous adipose-derived stem cell transplantation is safe and effective in promoting healing and alleviating symptoms in patients with chronic anal fissures. Similarly, a study in Stem Cell Research & Therapy reported significant improvements in pain scores and fissure healing rates following adipose-derived stem cell injections in patients with difficult-to-treat anal fissures. Platelet-rich plasma (PRP) injections, on the other hand, are minimally invasive and generally well-tolerated. They aim to accelerate the healing process without the need for surgery, making them appealing to patients seeking non-surgical treatment options. A randomized controlled trial published by The Wound Healing Society in 2023 evaluated the therapeutic effects of intralesional PRP in acute and chronic anal fissures compared to conventional topical treatments. The study concluded that PRP combined with topical products significantly outperformed topical treatments alone in anal fissure management.

Ongoing efforts in clinical research and development are expanding our understanding of regenerative mechanisms and refining treatment protocols for anal fissures. These endeavors are aimed at establishing the safety, efficacy, and long-term benefits of regenerative therapies in clinical practice. As research progresses and clinical trials validate their effectiveness and safety, regenerative therapies have the potential to transform the management of anal fissures, offering patients effective alternatives to traditional treatments.

Segmental Insights

Treatment Type Insights

Based on Treatment Type, the Topical Nitrates emerged as the dominating segment in the global market for Anal Fissure Treatment in 2023. Topical nitrates, such as nitroglycerin ointment, have shown strong effectiveness in clinical trials for treating anal fissures. They function by relaxing the internal anal sphincter muscle, which alleviates spasms and pain during bowel movements. This mechanism directly targets the root cause of anal fissures and promotes healing. Unlike surgical procedures, which can be invasive and require recovery time, topical nitrates provide a non-invasive treatment option. Patients prefer non-surgical methods that can be self-administered at home, avoiding hospital stays and anesthesia, which contributes to their increasing popularity. Topical nitrates are widely accessible in healthcare facilities, pharmacies, and via prescriptions. Their cost-effectiveness compared to surgical alternatives makes them appealing to healthcare providers and patients seeking economical treatment options. Ongoing research and development endeavors are continually refining the formulation and delivery of topical nitrates, aiming to enhance efficacy, reduce side effects, and improve patient outcomes. These advancements support the sustained expansion of this segment within the anal fissure treatment market.

Route of Administration Insights

Based on Route of Administration Type, Topical emerged as dominating segment in the global market for Anal Fissure Treatment in 2023. Topical treatments, such as ointments and creams applied directly to the affected area, have shown strong effectiveness in clinical trials for managing anal fissures. These treatments deliver medications directly to the fissure site, effectively addressing symptoms and promoting healing. Unlike oral medications or alternative administration methods, topical treatments offer a non-invasive approach. They are convenient for patients to apply themselves and typically result in fewer systemic side effects. Patients often prefer topical treatments due to their straightforward application directly to the affected area. These treatments are widely accessible in healthcare facilities, pharmacies, and through prescribed channels, ensuring availability for both patients and healthcare providers. Their broad accessibility contributes significantly to their dominance in the market. Clinical guidelines frequently recommend topical therapies as a primary treatment option for anal fissures, citing their well-established efficacy and safety profile. This endorsement encourages healthcare providers to prescribe topical treatments early in the treatment regimen, further solidifying their leading position in the market.

Regional Insights

Based on Region, North America emerged as the dominant region in the Global Anal Fissure Treatment Market in 2023. North America possesses a highly developed healthcare infrastructure featuring advanced medical facilities and widespread healthcare access. This facilitates early detection and treatment of anal fissures, which enhances market penetration. With one of the highest healthcare expenditures globally, driven by robust insurance coverage and healthcare policies, North America spends significantly more per person on healthcare compared to other high-income nations. For instance, health expenditures per person in the U.S. reached $12,555 in 2022, surpassing expenditures in comparable countries by over $4,000. This financial commitment enables patients to afford a wide array of treatment options, including surgical procedures and cutting-edge therapies. The region also benefits from extensive clinical research and well-established treatment guidelines, which promote the adoption of effective protocols for managing anal fissures.

Key Market Players

AbbVie Inc.

Novartis AG

Teva Pharmaceutical Industries Ltd.

RDD Pharma Ltd.

Cipla Limited

Sanofi SA

Boehringer Ingelheim International GmbH

Troikaa Pharmaceuticals Ltd.

Kyowa Kirin Co., Ltd.

Lupin Limited

Report Scope:

In this report, the Global Anal Fissure Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anal Fissure Treatment Market, By Treatment Type:

    Laxatives Topical Nitrates Calcium Channel Blockers Stool Softeners Surgery Others

Anal Fissure Treatment Market, By Route of Administration:

    Oral Topical Others

Anal Fissure Treatment Market, By Distribution Channel:

    Hospital Pharmacies Retail Pharmacies Online Pharmacies

Anal Fissure Treatment Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Anal Fissure Treatment Market.

Available Customizations:

Global Anal Fissure Treatment Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Impact of COVID-19 on Global Anal Fissure Treatment Market

5. Global Anal Fissure Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Type (Laxatives, Topical Nitrates, Calcium Channel Blockers, Stool Softeners, Surgery, Others)
    • 5.2.2. By Route of Administration (Oral, Topical, Others)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2023)
  • 5.3. Market Map

6. Asia Pacific Anal Fissure Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Anal Fissure Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. India Anal Fissure Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Type
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Australia Anal Fissure Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Type
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Distribution Channel
    • 6.3.4. Japan Anal Fissure Treatment Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Treatment Type
        • 6.3.4.2.2. By Route of Administration
        • 6.3.4.2.3. By Distribution Channel
    • 6.3.5. South Korea Anal Fissure Treatment Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Treatment Type
        • 6.3.5.2.2. By Route of Administration
        • 6.3.5.2.3. By Distribution Channel

7. Europe Anal Fissure Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Anal Fissure Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Type
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. Germany Anal Fissure Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Type
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. Spain Anal Fissure Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Type
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Anal Fissure Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment Type
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. United Kingdom Anal Fissure Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment Type
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Distribution Channel

8. North America Anal Fissure Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Anal Fissure Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. Mexico Anal Fissure Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Canada Anal Fissure Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel

9. South America Anal Fissure Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Anal Fissure Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Argentina Anal Fissure Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Colombia Anal Fissure Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Anal Fissure Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Anal Fissure Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment Type
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Saudi Arabia Anal Fissure Treatment Market Outlook
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment Type
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. UAE Anal Fissure Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment Type
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Anal Fissure Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. AbbVie Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
  • 15.2. Novartis AG
  • 15.3. Teva Pharmaceutical Industries Ltd.
  • 15.4. RDD Pharma Ltd.
  • 15.5. Cipla Limited
  • 15.6. Sanofi SA
  • 15.7. Boehringer Ingelheim International GmbH
  • 15.8. Troikaa Pharmaceuticals Ltd.
  • 15.9. Kyowa Kirin Co., Ltd.
  • 15.10. Lupin Limited

16. Strategic Recommendations

17. About Us & Disclaimer